Does Rallies show Form 4 insider transactions for RYTM?

Yes. Rallies tracks RYTM insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is RYTM research on Rallies investment advice?

No. Rallies provides research, data, and educational context for RYTM. It does not provide personalized investment advice.

RYTM (Rhythm Pharmaceuticals, Inc. Common Stock) Stock Analysis - Insider Trades

Rhythm Pharmaceuticals, Inc. Common Stock (RYTM) is a publicly traded Healthcare sector company. As of May 21, 2026, RYTM trades at $90.54 with a market cap of $5.95B and a P/E ratio of -28.53. RYTM moved +3.78% today. Year to date, RYTM is -11.02%; over the trailing twelve months it is +41.91%. Its 52-week range spans $45.91 to $122.20. Analyst consensus is strong buy with an average price target of $137.64. Rallies surfaces RYTM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading RYTM stock inside the company?

Recent RYTM insider activity includes German Christopher Paul sold 5.61K, Smith Hunter C sold 1.31K, Smith Hunter C sold 1.69K, Smith Hunter C sold 800, and Smith Hunter C sold 585. Rallies tracks insider transaction dates, shares, prices, and estimated values.

RYTM Key Metrics

Key financial metrics for RYTM
Metric	Value
Price	$90.54
Market Cap	$5.95B
P/E Ratio	-28.53
EPS	$-3.13
Dividend Yield	0.00%
52-Week High	$122.20
52-Week Low	$45.91
Volume	601
Avg Volume	0
Revenue (TTM)	$217.16M
Net Income	$-202.68M
Gross Margin	89.41%

Recent RYTM Insider Trades

German Christopher Paul sold 5.61K (~$502.79K) on Mar 4, 2026.
Smith Hunter C sold 1.31K (~$131.15K) on Feb 19, 2026.
Smith Hunter C sold 1.69K (~$170.75K) on Feb 19, 2026.
Smith Hunter C sold 800 (~$81.68K) on Feb 19, 2026.
Smith Hunter C sold 585 (~$60.42K) on Feb 19, 2026.

Latest RYTM News

Rhythm Pharmaceuticals jumps after Q1 revenue beat and new IMCIVREE obesity approvals — May 6, 2026
Rhythm Pharma rallies on Q1 IMCIVREE sales beat and fast HO launch uptake — May 5, 2026
Rhythm Pharma Sees 5% Q1 Sales Growth to $60.1M, Wins EU Nod, Targets Japan H2 — May 5, 2026
Rhythm Pharma rises ahead of May 5 earnings after recent IMCIVREE label expansion — May 4, 2026
Setmelanotide Shows 16.4% BMI Cut and 71.1% Weight-Category Gains in Pediatric Trial — May 4, 2026

RYTM Analyst Consensus

14 analysts cover RYTM: 0 strong buy, 14 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $137.64.

Common questions about RYTM

Who is trading RYTM stock inside the company?: Recent RYTM insider activity includes German Christopher Paul sold 5.61K, Smith Hunter C sold 1.31K, Smith Hunter C sold 1.69K, Smith Hunter C sold 800, and Smith Hunter C sold 585. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for RYTM?: Yes. Rallies tracks RYTM insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is RYTM research on Rallies investment advice?: No. Rallies provides research, data, and educational context for RYTM. It does not provide personalized investment advice.